A phase I open-label multi-center study of KFA115 as a single agent and in combination with tislelizumab in patients with select advanced cancers

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Cancers
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Non-small cell lung cancer with historic PD-L1 equal to or less than 1%, as determined locally using a clinically accepted assay. Patients must havemexperienced benefit from previous anti-PD(L) 1-containing therapymfor at least 4 months based on investigator-assessed disease stability or response prior to developing documented disease progression
    2. 2) Renal cell carcinoma, clear cell histology, previously treated with anti-PD(L)1-containing therapy and a VEGF targeted therapy as monotherapy or in combination
    3. 3) Cutaneous melanoma, previously treated with anti-PD(L)1-containing therapy

You may not be eligible for this study if the following are true:

    1. 1) Impaired cardiac function or clinically significant cardiac disease
    2. 2) Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study
    3. 3) History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.